Profound Medical Congratulates the Busch Center for Achieving 500th TULSA Procedure Milestone

About this update from Profound Medical Corp

[{"type":"text","content":"Profound Medical Congratulates the Busch Center for Achieving 500th TULSA Procedure MilestoneClinical validation from the Busch Center highlights the proven, scalable innovation driving a paradigm shift in prostate care — delivering precision treatment and better patient outcomes\n\n\n\n TORONTO, Oct. 16, 2025 (GLOBE NEWSWIRE) --\n \n\n Profound Medical Corp.\n \n\n (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today unveiled new, real-world data from the internationally recognized\n \n\n Busch Center\n \n\n . The data — marking the center’s milestone of 500 completed\n \n TULSA Procedures\n \n ™ — demonstrate the procedure’s versatility and success in treating a broad spectrum of prostate diseases, severities, and aggressions using a unique incision-free, MRI-guided approach.\n \n\n “When I first began performing the TULSA Procedure, I was optimistic but cautious. After about 30 procedures, I was confident enough to offer TULSA to my patients exclusively,” said Dr. Joseph Busch, Founder of the Busch Center. “I’ve had highly successful outcomes, even in the more complicated cases, such as those involving cancer at the prostate apex or calcifications that can make treatment more challenging. Fortunately, I have had many men referred to me by previous patients who had positive results, including good cancer control and no side effects like urinary incontinence and/or erectile dysfunction, and I have turned away only a very small number who I have felt would not benefit from undergoing the TULSA Procedure.”\n \n\n The TULSA Procedure is used by physicians to treat prostate cancer and benign prostatic hyperplasia (“BPH”, also known as an enlarged prostate). Among Dr. Busch’s cases, about half were for the primary treatment of prostate cancer, and one-third were for BPH, either alone or co-occurring with prostate cancer. The remainder were salvage patients previously treated with another therapy, a population with significant unmet need, to which TULSA’s inside-out approach is ideally suited.\n \n\n Early experience included focal and hemi-gla...

More updates from Profound Medical Corp